While Mylan’s EpiPen has dominated the epinephrine injection market for years, two new contenders are planning to launch versions... could these help relieve shortages? With no generic versions and few comparable alternatives, Mylan’s EpiPen has dominated the epinephrine injection device landscape for years. Meanwhile shortages have plagued the product, with continuing issues with the supply
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.